As these pathways can also be activated by EGFR, which is frequently overexpressed in pancreatic cancer, the combination of KAN0439834 with erlotinib or ibrutinib (which can also function as an EGFR inhibitor [194]) showed clear additive effects and highlighted the benefit of potential combinatory treatment strategies [193]. Here, EGFR is linked to pancreatic neoplasm.